MedDay Pharmaceuticals   Report issue

For profit Phase 1 Phase 3
Founded: Paris France (2011)
Status: No NME R&D (2011)

Organization Overview

First Clinical Trial
2013
NCT02220933
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

MedDay Pharmaceuticals SA | Medday Pharmeuticals | Medday SAS, Paris, France

Active Ingredients

Drugs in Phase 3 Trials (1)

biotin (10 trials)

Drugs in Phase 1 Trials (1)

moxifloxacin (avelox) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adrenoleukodystrophy (Phase 3)

Amyotrophic Lateral Sclerosis (Phase 2)

Charcot-Marie-Tooth Disease (Phase 2)

Hereditary Sensory and Motor Neuropathy (Phase 2)

Motor Neuron Disease (Phase 2)

Multiple Sclerosis (Phase 3)

Nerve Compression Syndromes (Phase 2)

Neuritis (Phase 3)

Optic Neuritis (Phase 3)

Peripheral Nervous System Diseases (Phase 2)

Polyneuropathies (Phase 2)

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (Phase 2)

Renal Insufficiency (Phase 1)

Sclerosis (Phase 3)

Tooth Diseases (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 10
  • # of Trial APIs: 2